Mission Pharmacal Header

Mission Pharmacal Header

X

Find Novel Drugs for Infections and Infectious Diseases under Discovery in FRANCE

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Mutabilis"},{"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"$425.0 million","newsHeadline":"Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"}]

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

Details:

The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases.

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Sanofi

Deal Size: $2,300.0 million Upfront Cash: $425.0 million

Deal Type: Expanded Collaboration June 23, 2020

Sanofi Company Banner

18th Oligonucleotide Therapeutics

Not Confirmed

envelop

Contact Supplier

Mutabilis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic Update

Details:

This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.

Lead Product(s): 2G-Dabocins

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Organovo Holdings

Deal Size: $11.9 million Upfront Cash: Undisclosed

Deal Type: Investment January 06, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY